Requirements:
Essential Functions:
The physical demands described here are representative of those that must be met by an employee to successfully perform the essential functions of this position. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
While performing the duties of this position, the employee is regularly required to talk or hear. The employee frequently is required to use hands or fingers, handle or feel objects, tools or controls. The employee is occasionally required to stand, walk, sit, reach with hands and arms, climb or balance, and stoop, kneel, crouch or crawl.
The employee must occasionally lift and/or move up to 25 pounds, and infrequently up to 50 pounds. Specific vision abilities required by this position include close vision, distance vision, color vision, peripheral vision, and the ability to adjust focus.
The noise level in the work environment is usually moderate.
Additional information:
Requests for medical, religious, and other exemptions will be considered on an individual basis. Breakthrough T1D will comply with all federal, state, and local laws.
Breakthrough T1D supports a diverse and inclusive workforce.
Breakthrough T1D is an Equal Opportunity Employer.
All your information will be kept confidential according to EEO guidelines.
Full-Time
Confirmed live in the last 24 hours
No salary listed
Senior, Expert
Company Does Not Provide H1B Sponsorship
Salt Lake City, UT, USA
The individual must reside in Utah.
Get referrals →
You have ways to get a Breakthrough T1D referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Indianapolis, Indiana
Founded
N/A
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Breakthrough T1D's annual Government Day brings nearly 200 volunteer advocates to Capitol Hill to encourage Congress to support critical type 1 diabetes researchRep. Kim Schrier, MD, lives with type 1 diabetes and is the first pediatrician elected to CongressWASHINGTON, March 4, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered volunteer advocates from across the country for its annual Government Day to encourage Congress to support T1D research, by renewing the Special Diabetes Program, preserving work being done at NIH and FDA, and protecting policies that will advance cell therapies.The Special Diabetes Program has accelerated the pace of T1D research through a critical long-term investment of funding at the National Institutes of Health. Made possible through bi-partisan support, the Special Diabetes Program has played a key role in nearly every significant T1D scientific advancement since its creation in 1997, including Tzield, the first disease-modifying therapy for T1D which can delay the onset of the disease by up to three years. The advocates began their day with a special breakfast address from Congresswoman Kim Schrier, MD (D-WA), who lives with T1D and is the first pediatrician elected to Congress."The Special Diabetes Program has fundamentally changed life for the 1.6 million Americans who, like me, live with type 1 diabetes. Breakthroughs like artificial pancreas technology and beta cell replacement therapies are possible because of the Special Diabetes Program. Congress must renew this program," said Breakthrough T1D Chief Global Advocacy Officer Lynn Starr
NEW YORK, Feb. 12, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to seven outstanding volunteer leaders whose impact has pushed the organization's mission forward. The volunteers were recognized with the awards at Breakthrough T1D's annual One Conference on Feb. 11, 2025. Award recipients include:Jordan Amis , Carol and Erwin Lurie Award, Award Dayton Coles , Dr. Gerald Fishbone Award, Dr
The Breakthrough T1D Play program is a medical research charity raising money for critical research into diabetes, one of the biggest causes of death in the U.S.And this week, gaming pioneer Will Wright helped raise money for the group, said Wright and said Josh Larson, national director of Breakthrough T1D Play, in interviews with GamesBeat. Wright talked about his career, making games like Sim City, The Sims and more at companies like Maxis and Electronic Arts. The Sims franchise has generated more than $5 billion in revenue to date.He’s now cofounder of his own startup Gallium Studios with Lauren Elliott and they’re working on a memory simulation game called Proxi. Wright, whose grandmother had T1D, also gave a sneak peek at what Proxi will be as part of a stream to raise money for the nonprofit.Will Wright’s new game is Proxi.Proxi is a new life simulation game about making magical connections with your memories and bringing them to life. The game is a lot like quantifying your memories, Wright said in an interview with GamesBeat.In an interview, Wright noted there are a couple of people in his family with T1D as well as other people among friends and at his workplace too. That gave him good reasons to do the stream with Breakthrough T1D Play.The Breakthrough T1D program focuses on cures for Type 1 diabetes, a disease which strikes one in 400 children
A positive recommendation for screening would expand access to T1D early detection and incorporate it into routine medical care. NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Today Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization announced a campaign to secure a recommendation for T1D screening from the United States Preventive Services Task Force (USPSTF). If obtained, such a positive recommendation would require all insurance plans to cover the cost of the screening and make early detection of T1D more accessible as part of routine preventive medical services. Early detection of T1D through screening, before symptoms appear and insulin is required, can help reduce the risk of life-threatening complications at diagnosis and allow people time to access a therapy that delays onset by an average of two years, participate in crucial T1D clinical trials, and prepare for future medical needs
GliaPharm, an EPFL spinoff biotech company, has received a BRAINS grant to support a four-year study on glial cell behavior in various neurological disorders. InSphero has partnered with Breakthrough T1D and ULB to develop treatments for type 1 diabetes, focusing on protecting insulin-producing beta cells while, Diramics has joined the EU-funded Move2THz project to advance high-frequency semiconductor technologies for various applications.